RRoche Read More Roche’s Oncology Pipeline Shows Promise in Treating Aggressive Brain Metastases2026-03-29 Roche’s trastuzumab, capecitabine, and tucatinib combo more than doubled median survival to 10 months in HER2+ breast cancer…